HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC-L’Oreal Settlement Will Fuel Cosmetics Class Actions – Attorney

This article was originally published in The Rose Sheet

Executive Summary

Class actions against cosmetics firms show no sign of slowing down, and FTC’s pending settlement with L’Oreal for gene-related anti-aging claims likely will spur further litigation in the sector, Edwards Wildman Palmer partner Ronie Schmelz says.

You may also be interested in...



Class Action Blight: The Sour Side Of Apple Stem Cell Anti-Aging Boom

Plant stem cell actives such as Mibelle Biochemistry's PhytoCellTec Malus Domestica were marquee ingredients for skin-care brands in the flourishing US anti-aging market years back. But what once was fruitful has turned rotten with regulatory crackdowns in recent years and class actions that continue to weigh on product manufacturers.

FTC-L’Oreal Settlement Should Reverberate Across Industry – Attorneys

The recent action against L’Oreal sends a signal to industry that FTC is paying attention to their claims. In an interview with “The Rose Sheet,” attorneys from Edwards Wildman Palmer discuss the case’s implications and whether it heralds a new FTC focus on cosmetics.

IFRA Implements New Methodology With 49th Amendment To Fragrance Safety Standards

The International Fragrance Association has given its ingredient safety standards a major overhaul based on a new methodology that accounts for aggregate exposure and an updated Quantitative Risk Assessment model for dermal sensitization.

Related Companies

UsernamePublicRestriction

Register

RS019115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel